Chemical structure and pharmacodynamics
The drug is a cyclopentyltriazolopyrimidine derivative with a chemical structure close to adenosine. Unlike thienopyridines (clopidogrel), ticagrelor is not a prodrug and does not require metabolic activation to exert its therapeutic effect.
The mechanism of action of the drug is based on non-competitive and reversible allosteric binding to platelet P2Y12 receptors. The drug binds to a receptor site distinct from the ADP binding site. Due to the reversibility of binding, platelet function inhibition resolves faster after drug discontinuation compared to thienopyridines.
Advantages over traditional agents
The key difference and clinical advantage of ticagrelor lie in the absence of resistance associated with genetic factors:
- The efficacy of the drug does not decrease in patients with low CYP2C19 isoenzyme activity.
- The antiplatelet effect develops faster than that of clopidogrel.
- Receptor binding is reversible, which makes it easier to predict bleeding risks if discontinuation is necessary.
Pharmacokinetics and dosing
Following oral administration, the substance is rapidly absorbed in the gastrointestinal tract, with a bioavailability of 36%. Metabolism occurs in the liver with the active participation of the CYP3A4 enzyme, resulting in an active metabolite that also possesses antiplatelet properties.
Due to relatively rapid elimination from the body and termination of action, the therapeutic regimen requires taking the drug twice daily.
Side Effects and Characteristics
The main systemic risk of therapy, common to the entire pharmacological group, is hemorrhagic complications (tendency to bleeding and hemorrhages).
A unique specific side effect is dyspnea (shortness of breath), which is observed in 10–20% of patients. This phenomenon is due to the structural similarity of the drug to adenosine and its direct effect on purine metabolism.
Briefly: answers to topical questions
What side effects does ticagrelor cause?
Ticagrelor causes hemorrhagic complications, such as the risk of bleeding and hemorrhages, characteristic of the entire drug class. Additionally, shortness of breath or dyspnea is frequently observed in 10–20% of patients, due to the structural similarity of ticagrelor to adenosine and its effect on adenosine metabolism.
Ticagrelor — NOT a prodrug (does not require activation), causes dyspnea (adenosine footprint), and is taken TWICE (two times) daily.
Class and exam questions
Is metabolic activation required for ticagrelor?
No, the drug is not a prodrug, possesses its own pharmacological activity, and does not require prior hepatic conversion to initiate action.
Why does ticagrelor need to be taken twice a day?
The dosing frequency is due to pharmacokinetic features — rapid elimination of the drug and the reversible nature of its binding to platelet receptors.
What causes shortness of breath when using the drug?
The symptom develops in 10–20% of patients due to the chemical similarity of the active substance to adenosine and its effect on the metabolism of this nucleoside.
What else to study on this topic
- Differences in pharmacodynamics between ticagrelor and thienopyridines (clopidogrel and prasugrel)
- The role of cytochrome CYP3A4 and the effect of inducers/inhibitors on drug concentration
- Interaction of ticagrelor with P-glycoprotein and concomitant pharmacotherapy
- Management tactics for patients who develop dyspnea while taking Brilinta
- Criteria for choosing antiplatelet therapy in acute coronary syndrome
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Ticagrelor" and another 5,304 pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Drugs affecting hemostasis and thrombosis"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.